JP2020073525A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020073525A5 JP2020073525A5 JP2019233649A JP2019233649A JP2020073525A5 JP 2020073525 A5 JP2020073525 A5 JP 2020073525A5 JP 2019233649 A JP2019233649 A JP 2019233649A JP 2019233649 A JP2019233649 A JP 2019233649A JP 2020073525 A5 JP2020073525 A5 JP 2020073525A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- score
- antigen
- antibody
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 49
- 239000000427 antigen Substances 0.000 claims 36
- 102000036639 antigens Human genes 0.000 claims 36
- 108091007433 antigens Proteins 0.000 claims 36
- 239000012634 fragment Substances 0.000 claims 36
- 208000000592 Nasal Polyps Diseases 0.000 claims 20
- 208000024891 symptom Diseases 0.000 claims 14
- 238000000034 method Methods 0.000 claims 12
- 201000009890 sinusitis Diseases 0.000 claims 10
- 238000011282 treatment Methods 0.000 claims 9
- 206010020751 Hypersensitivity Diseases 0.000 claims 8
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 8
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 8
- 208000026935 allergic disease Diseases 0.000 claims 8
- 208000006673 asthma Diseases 0.000 claims 8
- 230000009610 hypersensitivity Effects 0.000 claims 8
- 208000016366 nasal cavity polyp Diseases 0.000 claims 8
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 8
- 239000003246 corticosteroid Substances 0.000 claims 7
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 6
- 230000002146 bilateral effect Effects 0.000 claims 5
- 238000001356 surgical procedure Methods 0.000 claims 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 4
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 238000011156 evaluation Methods 0.000 claims 4
- 238000013095 identification testing Methods 0.000 claims 4
- 230000003434 inspiratory effect Effects 0.000 claims 4
- 238000007726 management method Methods 0.000 claims 4
- 210000004086 maxillary sinus Anatomy 0.000 claims 4
- 238000005259 measurement Methods 0.000 claims 4
- 238000012360 testing method Methods 0.000 claims 4
- 230000000007 visual effect Effects 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 2
- 229960002848 formoterol Drugs 0.000 claims 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 2
- 229960002744 mometasone furoate Drugs 0.000 claims 2
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims 2
- 206010039083 rhinitis Diseases 0.000 claims 2
- 229960004017 salmeterol Drugs 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229950003468 dupilumab Drugs 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021096260A JP2021138743A (ja) | 2013-06-21 | 2021-06-09 | Ｉｌ−４ｒアンタゴニストの投与により鼻茸を処置する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361837912P | 2013-06-21 | 2013-06-21 | |
| US61/837,912 | 2013-06-21 | ||
| EP14305670 | 2014-05-07 | ||
| EP14305670.3 | 2014-05-07 | ||
| JP2018243929A JP6640977B2 (ja) | 2013-06-21 | 2018-12-27 | Ｉｌ−４ｒアンタゴニストの投与により鼻茸を処置する方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018243929A Division JP6640977B2 (ja) | 2013-06-21 | 2018-12-27 | Ｉｌ−４ｒアンタゴニストの投与により鼻茸を処置する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021096260A Division JP2021138743A (ja) | 2013-06-21 | 2021-06-09 | Ｉｌ−４ｒアンタゴニストの投与により鼻茸を処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020073525A JP2020073525A (ja) | 2020-05-14 |
| JP2020073525A5 true JP2020073525A5 (enExample) | 2020-11-12 |
| JP6898421B2 JP6898421B2 (ja) | 2021-07-07 |
Family
ID=66440559
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018243929A Active JP6640977B2 (ja) | 2013-06-21 | 2018-12-27 | Ｉｌ−４ｒアンタゴニストの投与により鼻茸を処置する方法 |
| JP2019233649A Active JP6898421B2 (ja) | 2013-06-21 | 2019-12-25 | Ｉｌ−４ｒアンタゴニストの投与により鼻茸を処置する方法 |
| JP2021096260A Pending JP2021138743A (ja) | 2013-06-21 | 2021-06-09 | Ｉｌ−４ｒアンタゴニストの投与により鼻茸を処置する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018243929A Active JP6640977B2 (ja) | 2013-06-21 | 2018-12-27 | Ｉｌ−４ｒアンタゴニストの投与により鼻茸を処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021096260A Pending JP2021138743A (ja) | 2013-06-21 | 2021-06-09 | Ｉｌ−４ｒアンタゴニストの投与により鼻茸を処置する方法 |
Country Status (10)
| Country | Link |
|---|---|
| JP (3) | JP6640977B2 (enExample) |
| DK (1) | DK3010539T3 (enExample) |
| ES (1) | ES2747630T3 (enExample) |
| HR (1) | HRP20191709T1 (enExample) |
| HU (1) | HUE046410T2 (enExample) |
| LT (1) | LT3010539T (enExample) |
| NZ (1) | NZ631118A (enExample) |
| PT (1) | PT3010539T (enExample) |
| SG (1) | SG10201912898XA (enExample) |
| TW (1) | TWI707694B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116203244B (zh) * | 2022-03-30 | 2025-06-27 | 首都医科大学附属北京同仁医院 | 一种无创诊断2型慢性鼻窦炎伴鼻息肉的试剂盒 |
| CN116819076A (zh) * | 2023-05-26 | 2023-09-29 | 首都医科大学附属北京同仁医院 | 一种预测或评估抗IL-4Rα单抗在治疗慢性鼻窦炎伴鼻息肉中疗效的生物标志物、应用和方法 |
| CN117368487A (zh) * | 2023-09-28 | 2024-01-09 | 首都医科大学附属北京同仁医院 | 一种利用局部IgE预测或评估奥马珠单抗在治疗复发性鼻息肉中疗效的方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| EP2414520A2 (en) * | 2009-03-31 | 2012-02-08 | Altair Therapeutics, Inc. | Methods of modulating an immune response to a viral infection |
| UA111731C2 (uk) * | 2010-10-06 | 2016-06-10 | Рідженерон Фармасьютікалз, Інк. | Стабілізована композиція, яка містить антитіло до рецептора інтерлейкіну-4 (іl-4r), варіанти |
| KR20160024916A (ko) * | 2013-06-21 | 2016-03-07 | 사노피 바이오테크놀로지 | Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법 |
-
2014
- 2014-06-20 PT PT147420210T patent/PT3010539T/pt unknown
- 2014-06-20 NZ NZ631118A patent/NZ631118A/en unknown
- 2014-06-20 LT LTEP14742021.0T patent/LT3010539T/lt unknown
- 2014-06-20 ES ES14742021T patent/ES2747630T3/es active Active
- 2014-06-20 DK DK14742021.0T patent/DK3010539T3/da active
- 2014-06-20 TW TW108101935A patent/TWI707694B/zh active
- 2014-06-20 HR HRP20191709 patent/HRP20191709T1/hr unknown
- 2014-06-20 HU HUE14742021A patent/HUE046410T2/hu unknown
- 2014-06-20 SG SG10201912898XA patent/SG10201912898XA/en unknown
-
2018
- 2018-12-27 JP JP2018243929A patent/JP6640977B2/ja active Active
-
2019
- 2019-12-25 JP JP2019233649A patent/JP6898421B2/ja active Active
-
2021
- 2021-06-09 JP JP2021096260A patent/JP2021138743A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016523863A5 (enExample) | ||
| JP2023052458A5 (enExample) | ||
| RU2016101632A (ru) | Способы лечения полипоза носа путем введения антагониста il-4r | |
| JP2017535547A5 (enExample) | ||
| RU2017120437A (ru) | Способы лечения хронического синусита с полипами носа путем введения антагониста il-4r | |
| JP2023052457A5 (enExample) | ||
| JP2017507139A5 (enExample) | ||
| CA2918105C (en) | Methods for reducing exacerbation rates of asthma using benralizumab | |
| RU2016136364A (ru) | Способы лечения или предупреждения астмы посредством введения антагониста il-4r | |
| JP2020073525A5 (enExample) | ||
| JP2022160685A5 (enExample) | ||
| JP2015527364A5 (enExample) | ||
| JP2018512435A5 (enExample) | ||
| IL316408A (en) | A safe and effective method for treating psoriasis with a specific anti-IL23 antibody | |
| JP2020500152A5 (enExample) | ||
| KR102337599B1 (ko) | 벤랄리주맙을 이용하여 천식 환자에서 강제 호기량을 증가시키는 방법 | |
| JP2019529560A5 (enExample) | ||
| KR20240052871A (ko) | 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법 | |
| JP2024016237A5 (enExample) | ||
| US20230331834A1 (en) | Method of treating tendinopathy using interleukin-17 (il-17) | |
| JPWO2021237110A5 (enExample) | ||
| JPWO2021026205A5 (enExample) | ||
| HRP20191709T1 (hr) | Postupci liječenja nosne polipoze davanjem antagonista il-4r | |
| JP2019535716A5 (enExample) | ||
| RU2023120407A (ru) | Способы лечения или предотвращения астмы посредством введения антагониста il-4r |